Pharmacokinetics and pharmacodynamics of BB-10153, a thrombin-activatable plasminogen, in healthy volunteers

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 6, 2005, Pages 1180-1186

  Curtis, L D ^a   Brown, A ^a   Comer, M B ^a   Senior, J M ^a   Warrington, S ^b   Dawson, K M ^a,c  

^a British Biotechnology   (United Kingdom)

^b Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

^c Vernalis PLC   (United Kingdom)

Author keywords

Fibrinolysis; plasminogen; thrombin; thrombolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; BB 10153; D DIMER; FIBRIN; FIBRINOGEN; PLACEBO; PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; ANTIPLASMIN; BB-10153; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PLASMINOGEN; THROMBIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VIVO STUDY; MALE; PHASE 1 CLINICAL TRIAL; PLASMA HALF LIFE; PRIORITY JOURNAL; VOLUNTEER; ADOLESCENT; FIBRINOLYSIS; HALF LIFE TIME; METABOLISM; PHARMACOKINETICS;

ADOLESCENT; ADULT; ANTIPLASMIN; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HALF-LIFE; HUMANS; MALE; PHARMACOKINETICS; PLASMINOGEN; THROMBIN;

EID: 24644460885     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01352.x     Document Type: Article

References (11)

1. Dawson KM, Cook A, Devine JM, Edwards RM, Hunter MG, Raper RH, Roberts G. Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents. J Biol Chem 1994; 269: 15989-92.
2. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
3. Comer MB, Cackett KS, Gladwell S, Wood LM, Dawson KM. Thrombolytic activity of BB-10153, a thrombin-activatable plasminogen. J Thromb Haemost 2005; 3: 146-53.
4. White HD, Van de Werf FJ. Thrombolysis for myocardial infarction. Circulation 1998; 97: 1632-46.
5. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 1998; 79: 134-9.
6. Martin U, von Mollendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-74.
7. The GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
8. The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet 1999; 354: 716-22.
9. Spearman C. The proof and measurement of association between two things. Am J Psychol 1904; 15: 72-101.
10. Schott D, Dempfle C-E, Beck P, Liermann A, Mohr-Pennert A, Goldner M, Mehlem P, Azuma H, Schuster V, Mingers AM, Schwarz HP, Kramer MD. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. New Engl J Med 1998; 339: 1679-86.
11. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.